SAN FRANCISCO, CA, MapLight Therapeutics, a clinical-stage biopharmaceutical company announced the closing of an oversubscribed $225 million Series C financing led by Novo Holdings.
MapLight Therapeutics, a clinical-stage biopharmaceutical company announced the closing of an oversubscribed $225 million Series C financing led by Novo Holdings to continue the advancement of MapLight's transformative treatments for neuropsychiatric and neurological conditions. New investors, 5AM Ventures, Cowen Healthcare Investments, and others joined MapLight's existing syndicate in the financing.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
